Bradley McGregor (@bradmcg04) 's Twitter Profile
Bradley McGregor

@bradmcg04

Assistant Professor Harvard Medical School; Director of Clinical Research, Lank Center for GU Oncology DFCI COI -coi.asco.org/share/EXE-GEFM…

ID: 43356760

calendar_today29-05-2009 16:06:47

294 Tweet

1,1K Takipçi

143 Takip Edilen

Bradley McGregor (@bradmcg04) 's Twitter Profile Photo
Bradley McGregor
@bradmcg04

a year ago

NKT2152 an oral hf2 inhibitor with half life of 38 days has activity in heavily treated ccRCC with ORR 20% (26% with longer followup) with no unexpected toxicity. Trials ongoing exploring dose and activity following belzutifan - open Dana-Farber Lank Center for Genitourinary Oncology Toni Choueiri, MD

NKT2152 an oral hf2 inhibitor with half life of 38 days has activity in heavily treated ccRCC with ORR 20% (26% with longer followup) with no unexpected toxicity. Trials ongoing exploring dose and activity following belzutifan - open <a href="/DanaFarber_GU/">Dana-Farber Lank Center for Genitourinary Oncology</a> <a href="/DrChoueiri/">Toni Choueiri, MD</a>